Revance Therapeutics (RVNC) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall st set to open higher as chip stocks gain; US-Iran tensions in focus
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil eases as investors assess US-Iran peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update
February 28, 2022 4:05 PM EST- Announces the completion of three consecutive drug substance lots and one drug product lot as part of the qualification of new working cell bank, supporting BLA resubmission
- Fourth quarter and full year 2021 revenue for the RHA® Collection of dermal fillers of $23.8 million, and $70.8 million, respectively, with over 3,000 aesthetic accounts across products and services
- Cash, cash equivalents and short-term investments of $225.1 million
- Conference call and webcast today at 4:30 p.m. ET.
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company... More
